447 related articles for article (PubMed ID: 27372043)
21. Spironolactone and Resistant Hypertension in Heart Failure With Preserved Ejection Fraction.
Rossignol P; Claggett BL; Liu J; Vardeny O; Pitt B; Zannad F; Solomon S
Am J Hypertens; 2018 Mar; 31(4):407-414. PubMed ID: 29228101
[TBL] [Abstract][Full Text] [Related]
22. Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trial.
Selvaraj S; Claggett B; Shah SJ; Anand I; Rouleau JL; Desai AS; Lewis EF; Pitt B; Sweitzer NK; Pfeffer MA; Solomon SD
Eur J Heart Fail; 2018 Mar; 20(3):483-490. PubMed ID: 29148144
[TBL] [Abstract][Full Text] [Related]
23. Spironolactone Use and Improved Outcomes in Patients With Heart Failure With Preserved Ejection Fraction With Resistant Hypertension.
Tsujimoto T; Kajio H
J Am Heart Assoc; 2020 Dec; 9(23):e018827. PubMed ID: 33222584
[TBL] [Abstract][Full Text] [Related]
24. Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trials.
Ferreira JP; Cleland JG; Girerd N; Bozec E; Rossignol P; Pellicori P; Cosmi F; Mariottoni B; Solomon SD; Pitt B; Pfeffer MA; Shah AM; Petutschnigg J; Pieske B; Edelmann F; Zannad F
Eur J Heart Fail; 2023 Jan; 25(1):108-113. PubMed ID: 36303266
[TBL] [Abstract][Full Text] [Related]
25. Effect of Spironolactone on Exercise Tolerance and Arterial Function in Older Adults with Heart Failure with Preserved Ejection Fraction.
Upadhya B; Hundley WG; Brubaker PH; Morgan TM; Stewart KP; Kitzman DW
J Am Geriatr Soc; 2017 Nov; 65(11):2374-2382. PubMed ID: 28542926
[TBL] [Abstract][Full Text] [Related]
26. Diagnosis of Nonischemic Stage B Heart Failure in Type 2 Diabetes Mellitus: Optimal Parameters for Prediction of Heart Failure.
Wang Y; Yang H; Huynh Q; Nolan M; Negishi K; Marwick TH
JACC Cardiovasc Imaging; 2018 Oct; 11(10):1390-1400. PubMed ID: 29778859
[TBL] [Abstract][Full Text] [Related]
27. Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction.
O'Neal WT; Sandesara PB; Samman-Tahhan A; Kelli HM; Hammadah M; Soliman EZ
Eur J Prev Cardiol; 2017 Jul; 24(11):1212-1219. PubMed ID: 28482692
[TBL] [Abstract][Full Text] [Related]
28. Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spironolactone.
Cohen JB; Schrauben SJ; Zhao L; Basso MD; Cvijic ME; Li Z; Yarde M; Wang Z; Bhattacharya PT; Chirinos DA; Prenner S; Zamani P; Seiffert DA; Car BD; Gordon DA; Margulies K; Cappola T; Chirinos JA
JACC Heart Fail; 2020 Mar; 8(3):172-184. PubMed ID: 31926856
[TBL] [Abstract][Full Text] [Related]
29. Gender Differences in the Risk of Adverse Outcomes in Patients With Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction.
O'Neal WT; Sandesara P; Hammadah M; Venkatesh S; Samman-Tahhan A; Kelli HM; Soliman EZ
Am J Cardiol; 2017 Jun; 119(11):1785-1790. PubMed ID: 28395886
[TBL] [Abstract][Full Text] [Related]
30. Rationale and design of a multicentre, randomized, placebo-controlled trial of mirabegron, a Beta3-adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease Beta3-left ventricular hypertrophy (Beta3-LVH).
Pouleur AC; Anker S; Brito D; Brosteanu O; Hasenclever D; Casadei B; Edelmann F; Filippatos G; Gruson D; Ikonomidis I; Lhommel R; Mahmod M; Neubauer S; Persu A; Gerber BL; Piechnik S; Pieske B; Pieske-Kraigher E; Pinto F; Ponikowski P; Senni M; Trochu JN; Van Overstraeten N; Wachter R; Balligand JL
ESC Heart Fail; 2018 Oct; 5(5):830-841. PubMed ID: 29932311
[TBL] [Abstract][Full Text] [Related]
31. Sex Differences in Outcomes and Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction: A Secondary Analysis of TOPCAT Trial.
Merrill M; Sweitzer NK; Lindenfeld J; Kao DP
JACC Heart Fail; 2019 Mar; 7(3):228-238. PubMed ID: 30819379
[TBL] [Abstract][Full Text] [Related]
32. Spironolactone in Patients With Heart Failure, Preserved Ejection Fraction, and Worsening Renal Function.
Beldhuis IE; Myhre PL; Bristow M; Claggett B; Damman K; Fang JC; Fleg JL; McKinlay S; Lewis EF; O'Meara E; Pitt B; Shah SJ; Vardeny O; Voors AA; Pfeffer MA; Solomon SD; Desai AS
J Am Coll Cardiol; 2021 Mar; 77(9):1211-1221. PubMed ID: 33663739
[TBL] [Abstract][Full Text] [Related]
33. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction.
Solomon SD; Claggett B; Lewis EF; Desai A; Anand I; Sweitzer NK; O'Meara E; Shah SJ; McKinlay S; Fleg JL; Sopko G; Pitt B; Pfeffer MA;
Eur Heart J; 2016 Feb; 37(5):455-62. PubMed ID: 26374849
[TBL] [Abstract][Full Text] [Related]
34. Comparison of Predictors of Heart Failure With Preserved Versus Reduced Ejection Fraction in a Multiracial Cohort of Preclinical Left Ventricular Diastolic Dysfunction.
Zhang L; Liebelt JJ; Madan N; Shan J; Taub CC
Am J Cardiol; 2017 Jun; 119(11):1815-1820. PubMed ID: 28450040
[TBL] [Abstract][Full Text] [Related]
35. Diastolic Blood Pressure and Adverse Outcomes in the TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) Trial.
Sandesara PB; O'Neal WT; Kelli HM; Topel M; Samman-Tahhan A; Sperling LS
J Am Heart Assoc; 2018 Feb; 7(5):. PubMed ID: 29475874
[TBL] [Abstract][Full Text] [Related]
36. Racial Differences in Characteristics and Outcomes of Patients With Heart Failure and Preserved Ejection Fraction in the Treatment of Preserved Cardiac Function Heart Failure Trial.
Lewis EF; Claggett B; Shah AM; Liu J; Shah SJ; Anand I; O'Meara E; Sweitzer NK; Rouleau JL; Fang JC; Desai AS; Retta TM; Solomon SD; Heitner JF; Stamos TD; Boineau R; Pitt B; Pfeffer MA
Circ Heart Fail; 2018 Mar; 11(3):e004457. PubMed ID: 29664406
[TBL] [Abstract][Full Text] [Related]
37. Transition from asymptomatic diastolic dysfunction to heart failure with preserved ejection fraction: roles of systolic function and ventricular distensibility.
Aizawa Y; Sakata Y; Mano T; Takeda Y; Ohtani T; Tamaki S; Omori Y; Tsukamoto Y; Hirayama A; Komuro I; Yamamoto K
Circ J; 2011; 75(3):596-602. PubMed ID: 21282875
[TBL] [Abstract][Full Text] [Related]
38. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure.
Mottram PM; Haluska B; Leano R; Cowley D; Stowasser M; Marwick TH
Circulation; 2004 Aug; 110(5):558-65. PubMed ID: 15277317
[TBL] [Abstract][Full Text] [Related]
39. Prognostic Importance of Changes in Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone.
Shah AM; Claggett B; Sweitzer NK; Shah SJ; Deswal A; Anand IS; Fleg JL; Pitt B; Pfeffer MA; Solomon SD
Circ Heart Fail; 2015 Nov; 8(6):1052-8. PubMed ID: 26475142
[TBL] [Abstract][Full Text] [Related]
40. Sex-specific cardiovascular structure and function in heart failure with preserved ejection fraction.
Gori M; Lam CS; Gupta DK; Santos AB; Cheng S; Shah AM; Claggett B; Zile MR; Kraigher-Krainer E; Pieske B; Voors AA; Packer M; Bransford T; Lefkowitz M; McMurray JJ; Solomon SD;
Eur J Heart Fail; 2014 May; 16(5):535-42. PubMed ID: 24574260
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
